» Articles » PMID: 25841631

Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012

Overview
Specialty Hematology
Date 2015 Apr 6
PMID 25841631
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

West Nile virus (WNV) appeared for the first time in the United States in 1999 and rapidly spread across the Western hemisphere within a few years causing hundreds of thousands of human infections and significant disease. In 2002, it was found to be transmissible by blood transfusion, and within less than a year, nucleic acid testing for WNV RNA was in place for all US donations. The American Red Cross (ARC) collects approximately 40% of blood donations in the United States and closely monitors the results of such testing and evaluates donors found to be reactive. This review describes the 10-year results of the ARC testing program during the period 2003 to 2012. Overall, more than 27 million donations were tested during the transmission periods with 1576 RNA-positive donations identified. The temporal and geographic distributions of the infected donors are described. Methods to initiate and discontinue periods of individual donation testing were developed and validated to maximize safety. The nature of WNV infection among donors was investigated, and the distribution of viral titers was defined and was found to be no greater than 720000 RNA copies per milliliter. The distribution of titers by time sequence of appearance of antibodies was determined. Donors who were identified as being in the earliest stages of infection were evaluated for the appearance of symptoms, and 26% developed at least 3 characteristic symptoms. The testing program has been successful in preventing transmission of WNV by transfusion, and only 1 of the 13 reported cases since the initiation of testing was attributable to the Red Cross; it was from a granulocyte product transfused before availability of the test result.

Citing Articles

is a competent vector of five arboviruses affecting human health, greater Paris, France, 2023.

Bohers C, Vazeille M, Bernaoui L, Pascalin L, Meignan K, Mousson L Euro Surveill. 2024; 29(20).

PMID: 38757289 PMC: 11100294. DOI: 10.2807/1560-7917.ES.2024.29.20.2400271.


Leveraging Donor Populations to Study the Epidemiology and Pathogenesis of Transfusion-Transmitted and Emerging Infectious Diseases.

Bloch E, Busch M, Corash L, Dodd R, Hailu B, Kleinman S Transfus Med Rev. 2023; 37(4):150769.

PMID: 37919210 PMC: 10841704. DOI: 10.1016/j.tmrv.2023.150769.


Prevalence of anti-tick-borne encephalitis virus (TBEV) antibodies in Swiss blood donors in 2014-2015.

Ackermann-Gaumann R, Eyer C, Vock M, Gowland P, Tinguely C, Leib S Blood Transfus. 2022; 21(2):100-109.

PMID: 35969138 PMC: 10072989. DOI: 10.2450/2022.0099-22.


Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis.

Al-Heeti O, Wu E, Ison M, Saluja R, Ramsey G, Matkovic E Clin Infect Dis. 2022; 76(3):e1320-e1327.

PMID: 35883256 PMC: 9880244. DOI: 10.1093/cid/ciac566.


Mitigating the risk of transfusion-transmitted infections with vector-borne agents solely by means of pathogen reduction.

Stramer S, Lanteri M, Brodsky J, Foster G, Krysztof D, Groves J Transfusion. 2022; 62(7):1388-1398.

PMID: 35726756 PMC: 9541364. DOI: 10.1111/trf.16950.